Niagen Bioscience (NASDAQ:NAGE) Reaches New 12-Month High - Time to Buy?

Niagen Bioscience Inc (NASDAQ:NAGE - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $13.53 and last traded at $13.43, with a volume of 1329467 shares changing hands. The stock had previously closed at $12.95.

Wall Street Analyst Weigh In

Several research firms recently weighed in on NAGE. Wall Street Zen downgraded shares of Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research report on Friday. Canaccord Genuity Group raised their target price on Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, Roth Capital lifted their price target on shares of Niagen Bioscience from $10.00 to $23.00 and gave the company a "buy" rating in a research report on Friday.

Niagen Bioscience Stock Up 0.7%

The stock has a market cap of $1.06 billion, a P/E ratio of 79.53 and a beta of 2.08. The business has a 50 day simple moving average of $8.69.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.